Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 34,2024 No.11Detail

Analysis of the disease burden of bladder cancer attributed to smoking and high fasting blood glucose in five East Asian countries from 1990 to 2021

Published on Dec. 17, 2024Total Views: 68 timesTotal Downloads: 26 timesDownloadMobile

Author: ZHANG Jie 1 LU Mengxin 2 WEN Jun 3 LUAN Hanghang 4 HE Shaohua 5 ZI Hao 6 QIN Lihong 7 LUO Lisha 8

Affiliation: 1. Department of Retirement Affairs, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 2. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 3. Academic Discipline and Research Platform Development Office, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 4. Department of Forensic Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 5. Precision Medicine Center, The Second People's Hospital of Huaihua, Huaihua 418000, Hunan Province, China 6. Evidence-Based Medicine Center, Xiangyang No. 1 People's Hospital Affiliated to Hubei University of Medicine, Xiangyang 441000, Hubei Province, China 7. Wound & Stoma Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 8. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Keywords: Bladder cancer Smoking High fasting blood glucose Trends Disease burden

DOI: 10.12173/j.issn.1004-5511.202409132

Reference: Zhang J, Lu MX, Wen J, Luan HH, He SH, Zi H, Qin LH, Luo LS. Analysis of the disease burden of bladder cancer attributed to smoking and high fasting blood glucose in five East Asian countries from 1990 to 2021[J]. Yixue Xinzhi Zazhi, 2024, 34(11): 1199-1209. DOI: 10.12173/j.issn.1004-5511.202409132. [Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To study the disease burden of bladder cancer attributed to smoking and high fasting blood glucose (HFBG) among five East Asian countries from 1990 to 2021, providing a scientific basis for formulating bladder cancer prevention and control policies.

Methods  Data were sourced from the 2021 Global Burden of Disease study. The Joinpoint regression model was used to assess the temporal trends, and the age-period-cohort (APC) model was employed to evaluate the independent effects of age, period, and birth cohort on attributable burden.

Results  In 2021, China had the highest burden of bladder cancer attributed to smoking, while Japan had the highest burden attributed to HFBG. From 1990 to 2021, the smoking-attributed burden in the five East Asian countries showed declining trends (AAPC<0), with the largest decrease in South Korea (mortality rate-AAPC=-1.87%, DALY rate-AAPC=-2.29%). HFBG-attributed burden in China showed a declining trend (AAPC<0), whereas it exhibited increasing trends in North Korea (AAPC>0). APC results indicated that the age effects of both smoking and HFBG showed upward trends, peaking in the age group of 80 and above; the birth cohort effects for smoking-attributed rates in the five East Asian countries showed declining trends, while HFBG-attributed rates showed declining trends in all countries except North Korea.

Conclusion  Smoking and HFBG are significant independent risk factors for bladder cancer in the five East Asian countries, especially in China and Japan. Age is the main reason for the rising bladder cancer attributed burden, with the elderly being a high-risk population. Future prevention and control measures should target high-risk groups, improve residents’ awareness of smoking-related bladder cancer, and effectively reduce the incidence of diabetes to decrease the disease burden of bladder cancer.

Full-text
Please download the PDF version to read the full text: download
References

1. Global Burden of Disease Cancer Collaborators, Fitzmaurice C, Abate D, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2019, 5(12): 1749-1768. DOI: 10.1001/jamaoncol.2019.2996.

2. Karimi A, Shobeiri P, Azadnajafabad S, et al. A global, regional, and national survey on burden and quality of care index (QCI) of bladder cancer: the Global Burden of Disease Study 1990-2019[J]. PLoS One, 2022, 17(10): e0275574. DOI: 10.1371/journal.pone.0275574.

3. Huang Q, Zi H, Luo L, et al. Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030[J]. BMC Cancer, 2022, 22(1): 1164. DOI: 10.1186/s12885-022-10244-9.

4. Chavan S, Bray F, Lortet-Tieulent J, et al. International variations in bladder cancer incidence and mortality[J]. Eur Urol, 2014, 66(1): 59-73. DOI: 10.1016/j.eururo.2013. 10.001.

5. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100): 1345-1422. DOI: 10.1016/S0140-6736(17)32366-8.

6. Zi H, He SH, Leng XY, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019[J]. Mil Med Res, 2021, 8(1): 60. DOI: 10.1186/s40779-021-00354-z.

7. Lobo N, Afferi L, Moschini M, et al. Epidemiology, screening, and prevention of bladder cancer[J]. Eur Urol Oncol, 2022, 5(6): 628-639. DOI: 10.1016/j.euo.2022. 10.003.

8. Safiri S, Kolahi AA, Naghavi M, et al. Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. BMJ Glob Health, 2021, 6(11): e004128. DOI: 10.1136/bmjgh-2020-004128.

9. Xiong J, Yang L, Deng YQ, et al. The causal association between smoking, alcohol consumption and risk of bladder cancer: a univariable and multivariable Mendelian randomization study[J]. Int J Cancer, 2022, 151(12): 2136-2143. DOI: 10.1002/ijc.34228.

10. Liang R, Feng X, Shi D, et al. The global burden of disease attributable to high fasting plasma glucose in 204 countries and territories, 1990-2019: an updated analysis for the Global Burden of Disease Study 2019[J]. Diabetes Metab Res Rev, 2022, 38(8): e3572. DOI: 10.1002/dmrr.3572.

11. Naghavi M, Ong KL, Aali A, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990—2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2100-2132. DOI: 10.1016/S0140-6736(24)00367-2.

12. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2162-2203. DOI: 10.1016/S0140-6736(24)00933-4.

13. Mubarik S, Luo L, Iqbal M, et al. More recent insights into the breast cancer burden across BRICS-Plus: health consequences in key nations with emerging economies using the Global Burden of Disease Study 2019[J]. Front Oncol, 2023, 13: 1100300. DOI: 10.3389/fonc.2023. 1100300.

14. Jiang W, Xiang C, Du Y, et al. The global, regional and national burden of pancreatic cancer attributable to smoking, 1990 to 2019: a systematic analysis from the Global Burden of Disease Study 2019[J]. Int J Environ Res Public Health, 2023, 20(2): 1552. DOI: 10.3390/ijerph 20021552.

15. Jin Y, So H, Cerin E, et al. The temporal trend of disease burden attributable to metabolic risk factors in China, 1990-2019: an analysis of the Global Burden of Disease Study[J]. Front Nutr, 2022, 9: 1035439. DOI: 10.3389/fnut.2022.1035439.

16. Pei J, Shu T, Wu C, et al. Impact of human papillomavirus vaccine on cervical cancer epidemic: evidence from the surveillance, epidemiology, and end results program[J]. Front Public Health, 2023, 10: 998174. DOI: 10.3389/fpubh.2022.998174.

17. Liu X, Jiang J, Yu C, et al. Secular trends in incidence and mortality of bladder cancer in China, 1990-2017: a joinpoint and age-period-cohort analysis[J]. Cancer Epidemiol, 2019, 61: 95-103. DOI: 10.1016/j.canep. 2019.05.011.

18. Carstensen B. Age-period-cohort models for the Lexis diagram[J]. Stat Med, 2007, 26(15): 3018-3045. DOI: 10.1002/sim.2764.

19. Carstensen B, Plummer M, Laara E, Hills M (2024). Epi: statistical analysis in epidemiology. R package version 2.57, https://CRAN.R-project.org/package=Epi.

20. Ștefănescu ML, Tomescu PI, Forţofoiu MC, et al. Urinary bladder tumors clinical and statistical retrospective study[J]. Curr Health Sci J, 2018, 44(1): 64-70. DOI: 10.12865/CHSJ.44.01.11.

21. Al-Zalabani AH, Stewart KF, Wesselius A, et al. Modifiable risk factors for the prevention of bladder cancer: a systematic review of Meta-analyses[J]. Eur J Epidemiol, 2016, 31(9): 811-851. DOI: 10.1007/s10654-016-0138-6.

22. Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of bladder cancer[J]. Med Sci (Basel), 2020, 8(1): 15. DOI: 10.3390/medsci8010015.

23. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world[J]. World J Urol, 2009, 27(3): 289-293. DOI: 10.1007/s00345-009-0383-3.

24. Zhang G, Zhan J, Fu H. Trends in smoking prevalence and intensity between 2010 and 2018: implications for tobacco control in China[J]. Int J Environ Res Public Health, 2022, 19(2): 670. DOI: 10.3390/ijerph19020670.

25. Halaseh SA, Halaseh S, Alali Y, et al. A review of the etiology and epidemiology of bladder cancer: all you need to know[J]. Cureus, 2022, 14(7): e27330. DOI: 10.7759/cureus.27330.

26. Yang SL, Togawa K, Gilmour S, et al. Projecting the impact of implementation of WHO MPOWER measures on smoking prevalence and mortality in Japan[J]. Tob Control, 2024, 33(3): 295-301. DOI: 10.1136/tc-2022-057262.

27. Gill E, Sandhu G, Ward DG, et al. The sirenic links between diabetes, obesity, and bladder cancer[J]. Int J Mol Sci, 2021, 22(20): 11150. DOI: 10.3390/ijms222011150.

28. Jin YH, Zeng XT, Liu TZ, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)[J]. Mil Med Res, 2022, 9(1): 44. DOI: 10.1186/s40779-022-00406-y.

29. Global Burden of Disease 2019 Cancer Collaborators, Kocarnik JM, Compton K, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. JAMA Oncol, 2022, 8(3): 420-444. DOI: 10.1001/jamaoncol.2021.6987.

30. World Health Organization. WHO global report on trends in prevalence of tobacco use 2000-2025, fourth edition. (2021-11-14) [2024-08-10]. https://www.who.int/publications/i/item/9789240039322.

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us